Lv5
820 积分 2023-03-29 加入
Patenting perspective on Keap1 inhibitors (2019-2024)
1个月前
已完结
Patenting perspective on Keap1 inhibitors (2019-2024)
1个月前
已关闭
Neuronal FAM171A2 mediates α-synuclein fibril uptake and drives Parkinson’s disease
1个月前
已完结
From Reverse Phase Chromatography to HILIC: Graph Transformers Power Method-Independent Machine Learning of Retention Times
1个月前
已完结
QSARtuna: An Automated QSAR Modeling Platform for Molecular Property Prediction in Drug Design
2个月前
已完结
From Reverse Phase Chromatography to HILIC: Graph Transformers Power Method-Independent Machine Learning of Retention Times
2个月前
已完结
Calculating qualified non-mutagenic impurity levels: Harmonization of approaches
5个月前
已完结
Non-mutagenic impurities - Recent industry experience of using dose durational limits in drug development
5个月前
已完结
Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development
5个月前
已完结
利用拉曼光谱仪对氯氮平原料中杂质晶型的分析
9个月前
已关闭
皖公网安备34019202002308
